Sugi Predict

Sugi Predict / Compounds / SCHEMBL9900172

SCHEMBL9900172

SCHEMBL9900172

CC1(C)NC(=O)N(c2cnc(Cl)nc2)C1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 11/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ PGR P06401 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ ALOX12 P18054 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ POLB P06746 2/20 0.36
▸ ITGAL P20701 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9901073 0.81 ITGAL (0.42) ARRAB9AITGALALDH1A1
SCHEMBL11170138 0.77 AR (0.56) ARSMN1; SMN2MEN1LMNATP53
SCHEMBL1772990 0.76 AR (0.56) ARSMN1; SMN2MEN1LMNATP53
SCHEMBL1978963 0.76 AR (0.57) ARSMN1; SMN2MEN1LMNATP53
SCHEMBL1190896 0.76 AR (0.64) ARSMN1; SMN2MEN1LMNATP53
SCHEMBL16879149 0.75 AR (0.64) ARSMN1; SMN2MEN1LMNATP53
SCHEMBL11461814 0.75 AR (0.64) ARMEN1PGRKMT2APOLB
SCHEMBL21857732 0.73 AR (0.45) ARSMN1; SMN2RAB9APOLBHTT
SCHEMBL29913457 0.73 AR (0.45) ARSMN1; SMN2RAB9APOLBHTT
SCHEMBL14157436 0.73 AR (0.50) ARSMN1; SMN2MEN1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 — — US disclosed
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 — — US disclosed
US-11541052-B2 Compounds AUTIFONY THERAPEUTICS LIMITED (GB) 2023-01-03 — — US disclosed
US-11541052-B2 Compounds AUTIFONY THERAPEUTICS LIMITED (GB) 2023-01-03 — — US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 — — US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 — — US disclosed
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-12-14 — — US disclosed
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-12-14 — — US disclosed
US-20210023084-A1 NOVEL COMPOUNDS AUTIFONY SRL (IT) 2021-01-28 — — US disclosed
US-20210023084-A1 NOVEL COMPOUNDS AUTIFONY SRL (IT) 2021-01-28 — — US disclosed
CN-103596943-A Hydantoin derivatives useful as KV3 inhibitors AUTIFONY THERAPEUTICS LTD 2014-02-19 — — CN disclosed
WO-2013182850-A1 ISOBENZOFURAN- 5 -YL-OXY- (HETERO) ARYL - IMIDAZOLIDINE - 2, 4 -DIONE DERIVATIVES MODULATORS OF KV3 POTASSIUM CHANNELS FOR THE TREATMENT OF CNS DISORDERS. AUTIFONY THERAPEUTICS LIMITED (GB) 2013-12-12 — — WO disclosed
EP-2649066-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS Autifony Therapeutics Limited (GB) 2013-10-16 — — EP disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
CN-103328467-A Hydantoin derivatives useful as KV3 inhibitors AUTIFONY THERAPEUTICS LTD 2013-09-25 — — CN disclosed
WO-2013083994-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-06-13 — — WO disclosed
WO-2012168710-A1 HYDANTOIN DERIVATES AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-12-13 — — WO disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 AR 4850/4885SMN1; SMN2 2927/4885MEN1 1596/4885
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 AR 4850/4885SMN1; SMN2 2927/4885MEN1 1596/4885
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 AR 4863/4885SMN1; SMN2 3641/4885MEN1 1367/4885
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 AR 4850/4885SMN1; SMN2 2927/4885MEN1 1596/4885
US-20210023084-A1 NOVEL COMPOUNDS KCNN3, KCND3, KCNA3 AR 4441/4885SMN1; SMN2 832/4885MEN1 1640/4885
US-11541052-B2 Compounds KCNN3, KCNA3, KCNQ3 AR 4256/4885SMN1; SMN2 1150/4885MEN1 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.